Showing 1 posts of 1 posts found.

MyMD reports statistically significant results from phase 2 trial for sarcopenia/age-related frailty

August 2, 2023
Research and Development Musculo-skeletal disorder, MyMD, clinical trial, sarcopenia

MyMD Pharmaceuticals has announced statistically significant positive topline results from a phase 2 trial of oral TNF- α inhibitor, MYMD-1 …

Latest content